Sofpironium bromide

Sofpironium bromide, sold under the brand name Ecclock among others, is a medication used to treat hyperhidrosis (excessive sweating). It is an anticholinergic and is applied to the skin.

It was approved in Japan in 2020, for the treatment of primary axillary hyperhidrosis. It was approved for medical use in the United States in June 2024.

Medical uses
Sofpironium bromide is indicated for the treatment of primary axillary hyperhidrosis.

Mechanism of action
Sofpironium bromide is an anticholinergic agent that reduces sweating by inhibiting M3 muscarinic receptors in eccrine glands. It is a retrometabolically-designed drug (or "soft drug") based on glycopyrronium bromide, meaning it has been designed to exert the desired effects at the site of administration, after which it is quickly converted into an inactive non-toxic metabolite upon entering systemic circulation avoiding the typical anticholinergic side-effects caused by off-site action.

Brand names
Sofpironium bromide is the international nonproprietary name.

It is marketed as Ecclock in Japan and as Sofdra in the US.